Related video above: Moderna working to have COVID-19 vaccines for children as young as 5 by early fallModerna has released its latest findings from a third-phase study of patients receiving its COVID-19 vaccine.According to a release from the company, the data shows 93% efficacy six months after the second dose. The Massachusetts-based company also said a study in its second phase "induced robust antibody responses" against the gamma, beta and delta variants of COVID-19 for three booster candidates. The company has submitted this data to a peer-reviewed journal for publication. The company also has ongoing efficacy studies for adolescents aged 12 to 17 and for pediatric patients age 6 months to 11 years old.
Related video above: Moderna working to have COVID-19 vaccines for children as young as 5 by early fall
Moderna has released its latest findings from a third-phase study of patients receiving its COVID-19 vaccine.
According to a release from the company, the data shows 93% efficacy six months after the second dose.
The Massachusetts-based company also said a study in its second phase "induced robust antibody responses" against the gamma, beta and delta variants of COVID-19 for three booster candidates. The company has submitted this data to a peer-reviewed journal for publication.
The company also has ongoing efficacy studies for adolescents aged 12 to 17 and for pediatric patients age 6 months to 11 years old.
Source link
